A 4-nitrobenzofuroxan derivative, designated XI-006 (NSC207895) was identified and was shown to repress MDM4 promoter activity resulting in decreased MDM4 mRNA and protein expression and cell viability in MDM4 amplified breast cancer cell lines18. Here, MDM4 is linked to breast carcinoma.